Assessment of the Prevalence of Steatotic Liver Disease Associated with Metabolic Dysfunction in Patients with Heterozygous Familial Hypercholesterolemia

Inclusion Criteria:

• Patient aged 35 or over

• Consultation at Nantes, Rennes or Angers University Hospital during the inclusionperiod

• With a diagnosis of familial hypercholesterolemia defined by the presence of agenetic variant, ACMG classes 4 & 5 on LDLR, APOB or PCSK9

• Patient not objecting to inclusion in study (no written objection)

Exclusion Criteria:

• Protected patients: minors, adults under guardianship, curatorship and/or safeguardof justice

• Pregnant or breast-feeding

• Active viral hepatitis

• Hemochromatosis

• Other genetic or autoimmune hepatitis

• Current treatment with a drug likely to cause hepatic steatosis, includingamiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals

• Current oral corticosteroid therapy unless dose has been stable for ≥ 3 months

• Current pathological alcohol consumption (≥ 60 g/day in men and ≥ 50 g/day in women)